On August 23, 2019, the US Food and Drug Administration (FDA) approved Takhzyro® (lanadelumab-flyo) for the prevention of hereditary angioedema (HAE) attacks in children...
Cybin Inc., a leading psychedelic pharmaceutical company, recently announced that it has received regulatory approval for its first-in-human clinical trial of its CYB004 molecule,...
The Menarini Group, a global pharmaceutical company, recently announced that its subsidiary Stemline Therapeutics has received U.S. Food and Drug Administration (FDA) approval for...
The U.S. Food and Drug Administration (FDA) recently granted orphan-drug exclusivity to Xeris Biopharma’s Recorlev® for the treatment of hypoglycemia in adults with diabetes....
The U.S. Food and Drug Administration (FDA) recently approved Guardant Health’s Guardant360® CDx as a companion diagnostic for Menarini Group’s ORSERDU™ (fulvestrant) to treat...
Looks like you are using an ad-blocking browser extension. We request you to whitelist our website on the ad-blocking extension and refresh your browser to view the content.
